Global scaling for semi-quantitative analysis in FP-CIT SPECT
暂无分享,去创建一个
H Amthauer | W Brenner | I. Apostolova | H. Amthauer | R. Buchert | W. Brenner | C. Lange | R Buchert | D Kupitz | I Apostolova | C Lange | G Ulrich | G. Ulrich | D. Kupitz
[1] D. Guilloteau,et al. Visualization of the Dopamine Transporter in the Human Brain Postmortem with the New Selective Ligand [125I]PE2I , 1999, NeuroImage.
[2] Ralph Buchert,et al. IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[3] G. Pearlson,et al. Basal ganglia volume in adults with Down syndrome , 1997, Psychiatry Research: Neuroimaging.
[4] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[5] N. Verhoeff,et al. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] J D Speelman,et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[7] A. Antonini,et al. EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease , 2013, European journal of neurology.
[8] Eileen O. Smith,et al. Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.
[9] D. Jennings,et al. Optimized, Automated Striatal Uptake Analysis Applied to SPECT Brain Scans of Parkinson's Disease Patients , 2007, Journal of Nuclear Medicine.
[10] Koen Van Laere,et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Perry E Radau,et al. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] G. Knudsen,et al. Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I , 2010, The Journal of Nuclear Medicine.
[13] John S. Fleming,et al. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Osama Sabri,et al. Value of Semiquantitative Analysis for Clinical Reporting of 123I-2-β-Carbomethoxy-3β-(4-Iodophenyl)-N-(3-Fluoropropyl)Nortropane SPECT Studies , 2013, The Journal of Nuclear Medicine.
[15] Z Walker,et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.
[16] K. Tatsch,et al. Quantitative approaches to dopaminergic brain imaging. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[17] S. Gacinovic,et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.
[18] D. Brooks,et al. [123I]β-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson’s disease and multiple system atrophy , 2003, Nuklearmedizin.
[19] Paul J. Laurienti,et al. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets , 2003, NeuroImage.
[20] Klaus Tatsch,et al. Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update , 2013, The Journal of Nuclear Medicine.
[21] Wim Vandenberghe,et al. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[22] K. Laere,et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[23] M Laruelle,et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[24] L. Timmermann,et al. 123I-FP-CIT SPECT imaging of the dopaminergic state , 2012, Nuklearmedizin.
[25] John Seibyl,et al. SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* , 2012, The Journal of Nuclear Medicine.
[26] W. Koch,et al. Equipment-independent reference values for dopamine transporter imaging with 123I-FP-CIT , 2007, Nuklearmedizin.
[27] Sylvain Houle,et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? , 2005, Nuclear medicine and biology.
[28] Dae Hyuk Moon,et al. Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.